Document:

EX-10.1A

 Exhibit 10.1(a) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 LICENSE AGREEMENT 

BETWEEN 
 NEOTOPE
BIOSCIENCES LIMITED 
 AND 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 

FOR 
 CASE NO. SD2002-035 

 TABLE OF CONTENTS 

 

							
			
	 ARTICLE 1.
	 	 DEFINITIONS
	  	 	2	 
			
	 ARTICLE 2.
	 	 GRANTS
	  	 	4	 
			
	 ARTICLE 3.
	 	 CONSIDERATION
	  	 	5	 
			
	 ARTICLE 4.
	 	 REPORTS, RECORDS AND PAYMENTS
	  	 	9	 
			
	 ARTICLE 5.
	 	 PATENT MATTERS
	  	 	12	 
			
	 ARTICLE 6.
	 	 GOVERNMENTAL MATTERS
	  	 	14	 
			
	 ARTICLE 7.
	 	 TERMINATION OR EXPIRATION OF THE AGREEMENT
	  	 	15	 
			
	 ARTICLE 8.
	 	 LIMITED WARRANTY AND INDEMNIFICATION
	  	 	16	 
			
	 ARTICLE 9.
	 	 USE OF NAMES AND TRADEMARKS
	  	 	17	 
			
	 ARTICLE 10.
	 	 MISCELLANEOUS PROVISIONS
	  	 	18	 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 LICENSE AGREEMENT 

This agreement (“Agreement”) is made by and between NEOTOPE BIOSCIENCES LIMITED, a private limited company incorporated under the laws of
Ireland with offices at 25- 28 North Wall Quay, Dublin 1, Ireland (“LICENSEE”) and The Regents of the University of California, a California corporation having its statewide administrative offices at
1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Technology Transfer Office, Mail Code 0910, 9500 Gilman Drive, La Jolla,
California 92093-0910 (“UCSD”). 
 This Agreement is effective on the date of the last signature (“Effective Date”). 

RECITALS 
 WHEREAS, the inventions
disclosed in UCSD Disclosure Docket No. SD2002-035 and titled “DEVELOPMENT OF AN ANTI-PARKINSON’S VACCINE IN TRANSGENIC MICE” (“Invention”), was made in part by employees of
Elan Pharmaceuticals, Inc. (“Elan”), predecessor in interest to Licensee, and arose in part from research at UCSD by Dr. Eliezer Masliah and his associates (hereinafter and collectively, the “Inventors”) and are covered by
Patent Rights as defined below; 
 WHEREAS, the development of the Invention was sponsored in part by Elan and as a consequence this license is
subject to overriding obligations to the same under the sponsorship agreement; 
 WHEREAS, the sponsorship agreement referred to above included the transfer
of sponsor’s material to UNIVERSITY and provisions limiting the use of said material; 
 WHEREAS, Elan assigned its rights in the Invention to
Licensee; 
 WHEREAS, the Inventors are employees of UCSD, and they are obligated to assign all of their right, title and interest in the Invention
to UNIVERSITY; 
 WHEREAS, LICENSEE entered into a secrecy agreement (UC Control
No. 2012-20-0615) with UNIVERSITY, effective 5/15/2012, for the purpose of evaluating the Invention (the “Secrecy Agreement”); 

WHEREAS, LICENSEE entered into Option Agreements (UC Control
No. 2004-12-0016 and 2007-12-0032) with UNIVERSITY, effective 4/1/2003 and 7/11/2006
respectively, arising from the sponsorship agreement; 
 WHEREAS, UNIVERSITY is desirous that the Invention be developed and utilized to the fullest
possible extent so that its benefits can be enjoyed by the general public; 
 WHEREAS, LICENSEE is desirous of obtaining certain rights from
UNIVERSITY for commercial development, use, and sale of the Invention, and the UNIVERSITY is willing to grant such rights; and 
 WHEREAS, LICENSEE
understands that UNIVERSITY may publish or otherwise disseminate information concerning the Invention at any time and that LICENSEE is paying consideration thereunder for its early access to the Invention not continued secrecy therein. 

  
 1 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 NOW, THEREFORE, the parties agree: 

ARTICLE 1. DEFINITIONS 
 The terms, as
defined herein, shall have the same meanings in both their singular and plural forms. 
 1.1    “Affiliate” means any
corporation or other business entity which is bound in writing by LICENSEE to the terms set forth in this Agreement and in which LICENSEE owns or controls, directly or indirectly, at least fifty percent (50%) of the outstanding stock or other voting
rights entitled to elect directors, or in which LICENSEE is owned or controlled directly or indirectly by at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors; but in any country where the local
law does not permit foreign equity participation of at least fifty percent (50%), then an “Affiliate” includes any company in which LICENSEE owns or controls or is owned or controlled by, directly or indirectly, the maximum percentage of
outstanding stock or voting rights permitted by local law. 
 1.2    “Combination Product” means any product which is a
Licensed Product (as defined below) and contains other product(s) or product component(s) that is not an excipient, diluent, adjuvant, buffer and the like and (i) does not use Invention, or Patent Rights (as defined below); (ii) the sale, use
or import by itself does not contribute to or induce the infringement of Patent Rights; (iii) is sold separately by LICENSEE, its Sublicensee (as defined below) or an Affiliate; and (iv) enhances the market price of the final product(s)
sold, used or imported by LICENSEE, its Sublicensee, or an Affiliate. 
 1.3    “Commercially Reasonable Efforts” means that
the LICENSEE will use the efforts of a similarly situated company in its industry entrusted with the exercise of rights under an exclusive patent license but the level of effort will be no less than: (a) marketing Licensed Products in
quantities calculated to address anticipated market demand once marketing has begun and (b) seeking needed governmental approvals for marketing Licensed Products with diligence in supplying indicated information to, and replying to, appropriate
governmental offices in the process. Commercially Reasonable Efforts shall in no case involve a shelving of the development, marketing or sale of Licensed Products or a suspension of the diligent pursuit of needed governmental approval for Licensed
Products. 
 1.4    “Field” means diagnostic, therapeutic and prophylactic uses, excluding [***]. 

1.5    “Licensed Method” means any method that is covered by a Valid Claim the use of which would constitute, but for the
license granted to LICENSEE under this Agreement and Licensee’s co-ownership interest, an infringement, an inducement to infringe or contributory infringement, of any pending or issued claim within Patent
Rights, had LICENSEE not had rights in patents and patent applications claiming Invention. 
 1.6    “Licensed Product” means
any service, composition or product that is covered by a Valid Claim and the manufacture, use, sale, offer for sale, or importation of which would constitute, but for the license granted to LICENSEE under this Agreement and Licensee’s co-ownership interest, an infringement, an inducement to infringe or contributory infringement, of any pending or issued claim within the Patent Rights, had LICENSEE not had rights in patents and patent applications
claiming Invention. 

  
 2 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 1.7    “Net Sales” means the gross amount charged for Licensed Products sold
by LICENSEE, Sublicensees and/or Affiliates to third parties, less the sum of (a) and (b) where applicable and if reasonable, separately listed, (a) is a provision for (i) reasonable cash, trade, and quantity discounts or rebates
other than price discounts granted at the time of the sale (as allowed under applicable law), reasonable service allowances and reasonable broker’s or agent’s commissions, if any, actually allowed or paid, (ii) credits or allowances
actually given or made for rejection or return of, previously sold products or retroactive price reductions (including Medicaid, Medicare, government, commercial and similar types of rebates), (iii) sales tax, use tax, tariff, import/export duties
or other excise taxes or other governmental charges levied on, attributable to or measured by the billing amount (excluding income, franchise, and value added taxes except to the extent that value added taxes have actually been paid and are not
reimbursable), as adjusted for rebates and refunds, (iv) transportation, freight and insurance charges actually incurred and directly related to the distribution of the Licensed Products (excluding amounts reimbursed by third party customers),
(v) reasonable credits or allowances actually given or made for wastage replacement, and (vi) taxes paid by LICENSEE, Sublicensees and/or Affiliates to the United States Government or an instrumentality thereof under 42 U.S.C. 300 aa-1 et seq. or other similar legislation, or to a State of the United States or to a government of any other country or portion thereof insuring against liability arising out of the manufacture, use or sale of
Licensed Products by LICENSEE, Sublicensees and/or Affiliates; and (b) is a periodic adjustment of the provision determined in (a) to reflect amounts actually incurred for (i), (ii), (iii), (iv), and (v). A “Sale” of a Licensed
Product is deemed to occur upon the invoicing, or if no invoice is issued, upon the earlier of shipment or transfer of title in the Licensed Product to a third party. For purposes of calculating Net Sales, transfers to a Sublicensee or an Affiliate
of Licensed Product under this Agreement for (i) end use (but not resale) by the Sublicensee or Affiliate shall be treated as sales by LICENSEE at list price of LICENSEE, or (ii) resale by a Sublicensee or an Affiliate shall be treated as
sales at the list price of the Sublicensee or Affiliate. 
 1.8    “Patent Costs” means all expenses for the preparation,
filing, prosecution, and maintenance of all United States and foreign patents included in Patent Rights. Patent Costs shall also include out-of-pocket expenses for
patentability opinions, inventorship determination, preparation and prosecution of patent application, re-examination, re-issue, interference, and opposition activities
related to patents or applications in Patent Rights. 
 1.9    “Patent Rights” means UNIVERSITY’s rights in any the US
and foreign patent applications described un Exhibit A disclosing and claiming the Invention, filed by Inventors and assigned to UNIVERSITY; and continuing applications thereof including divisions, substitutions, and
continuations-in-part (but only to the extent the claims thereof are entirely supported in the specification and entitled to the priority date of the parent
application); any patents issuing on said applications including reissues, reexaminations and extensions; and any corresponding foreign applications or patents. 

1.10    “Sublicense” means an agreement into which LICENSEE enters with a third party that is not an Affiliate for the purpose
of (i) granting certain rights; (ii) granting an option to certain rights; or (iii) forbearing the exercise of any rights, granted to LICENSEE under this Agreement. 

1.11    Sublicense Fees” means all issue fees, milestone payments and similar license fees received by LICENSEE from its Sublicensees
in consideration for the grant of a Sublicense, but excluding: (i) earned royalties based on sales of Licensed Products; (ii) research 

  
 3 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 
payments and reimbursement of research or development costs or expenses which are explicitly earmarked for research and development activities in a specific contract (entered into after the
Effective Date of this Agreement) with a Sublicensee towards the commercialization of Licensed Products; (iii) amounts paid for purchase of stock or other equity or debt interests in LICENSEE, provided that if such equity investments are at a
price greater than fair market value, the premium shall be included in Sublicense Fees; (iv) reimbursement of patent costs and other out-of-pocket costs incurred in
connection with filing, prosecuting, and/or maintaining the Patent Rights; and (v) payments received for the supply of goods (including Licensed Products) or services, which is subject to the provisions of Paragraph 3.1d or 3.1f (as
applicable). 
 1.12    “Term” means the period of time beginning on the Effective Date and ending on the expiration date of
the longest-lived Patent Rights. 
 1.13    “Territory” means worldwide where Patent Rights exist. 

1.14    “Valid Claim” means any claim of an issued and unexpired patent within Patent Rights that has not been held
unenforceable, unpatentable or invalid by a decision of a court or governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal. 

ARTICLE 2. GRANTS 

2.1    License. Subject to the limitations set forth in this Agreement, UNIVERSITY hereby grants to LICENSEE and Affiliates, and
LICENSEE hereby accepts, a exclusive license, with the right of Sublicense, under UNIVERSITY’s rights in Patent Rights to make and have made, to use and have used, to sell and have sold, to offer for sale, and to import and have imported
Licensed Products and to practice Licensed Methods in the Field within the Territory and during the Term. LICENSEE agrees to be responsible for Affiliates performance of and compliance with the terms of this Agreement. 

The license granted herein is exclusive for University’s interests in the Patent Rights. 

2.2    Sublicense. 

(a)    The license granted in Section 2.1 includes the right of LICENSEE to grant Sublicenses of UNIVERSITY’s
interest in the Patent Rights to third parties during the Term but only for as long as this license is exclusive. 

(b)    With respect to Sublicense granted pursuant to Paragraph 2.2(a), LICENSEE shall: 

(i)    not receive, or agree to receive, anything of value in lieu of cash as consideration from a third party under a
Sublicense granted to a Sublicensee without the express written consent of UNIVERSITY. 
 The supply of goods, services, or leased space
between the Licensee and Sublicensee shall not be considered non-cash consideration under this paragraph to the extent the supply of goods, services, or leased space are at fair market value for dealings with
unrelated third parties and with no premium due to the sublicensed rights in the Patent Rights. 

  
 4 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 (ii)    to the extent applicable, include in any Sublicense all of the
rights of and obligations due to UNIVERSITY and contained in this Agreement; 
 (iii)    promptly provide UNIVERSITY with
a copy of each Sublicense issued, which shall be LICENSEE’s Confidential Information and shall be held in confidence as set forth in Section 10.2. LICENSEE may redact those portions of a Sublicense that do not relate to this Agreement.

 (iv)    collect and guarantee payment of all payments due, directly or indirectly, to UNIVERSITY from any Sublicensees
and summarize and deliver all reports due, directly or indirectly, to UNIVERSITY from Sublicensees. 
 (c)    Upon
termination of this Agreement for any reason, UNIVERSITY, at its sole discretion, shall determine whether LICENSEE shall cancel or assign to UNIVERSITY any and all Sublicenses. 

(d)    If LICENSEE grants a license to a third party under its own interest in any Patent Rights, LICENSEE shall also
concurrently grant a Sublicense under Patent Rights to said third party under this Section 2.2. 
 2.3    Reservation of
Rights. Subject to Sections 2.3(d) and (e), UNIVERSITY reserves the right to: 
 (a)    use the Invention and
Patent Rights for educational and research purposes; and 
 (b)    publish or otherwise disseminate any information about
the Invention at any time; and; 
 (c)    allow other nonprofit institutions to use and publish or otherwise disseminate
any information about Invention and Patent Rights for educational and research purposes. 
 (d)    For the avoidance of
doubt, the provisions of that certain Research Agreement dated September 1, 2001 between UNIVERSITY and Elan Pharma International Limited, predecessor in interest to LICENSEE, and its seven amendments, limiting use and transfer of the material
continue to apply under this Agreement. 
 (e)    UNIVERSITY shall request Dr. Eliezer Masliah to notify the
UNIVERSITY’s licensing professional responsible for the administration of this Agreement who agrees to provide notice to any corporate sponsor that approaches him with a similar antibody for work in the same therapeutic area that
(i) UNIVERSITY’s Patent Rights have been exclusively licensed, and (ii) LICENSEE has patent rights solely owned by LICENSEE , including compositions that may be relevant to the material the potential sponsor is proposing to use in the
research project. LICENSEE agrees that UNIVERSITY may provide any such potential sponsor notified under this paragraph 2.3e contact information of LICENSEE. 

ARTICLE 3. CONSIDERATION 

3.1    Fees and Royalties. The parties hereto understand that the fees and royalties payable by LICENSEE to UNIVERSITY under this
Agreement are partial consideration for the 

  
 5 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 
license granted herein to LICENSEE and Affiliates under Patent Rights. LICENSEE shall pay UNIVERSITY: 

(a)    a license issue fee of [***], within [***] days after the Effective Date; 

(b)    license maintenance fees of [***] per year and payable on the first anniversary of the Effective Date and annually
thereafter on each anniversary; provided however, that LICENSEE’s obligation to pay this fee shall end on the date when LICENSEE is commercially selling a Licensed Product; 

(c)    one-time milestone payments in the amounts payable according to the
following schedule or events for each Licensed Product, each payment being due and payable one time only and within [***] days after the occurrence of the corresponding event: 

 

					
	 Amount
	  	 Date or Event

	(i)	 	 [***]
	  	IND acceptance
			
	(ii)	 	 [***]
	  	First patient dosed in a Phase II clinical trial using a Licensed Product
			
	(iii)	 	 [***]
	  	First patient dosed in a Phase III clinical trial using a Licensed Product
			
	(iv)	 	 [***]
	  	Filing for regulatory approval of a Licensed Product in the US or equivalent application outside the US
			
	(v)	 	 [***]
	  	Regulatory approval for a Licensed Product in the US
			
	(vi)	 	 [***]
	  	Regulatory approval of a Licensed Product in Europe
			
	(vii)	 	 [***]
	  	Regulatory approval of a Licensed Product in Japan
			
	(viii)	 	 [***]
	  	Regulatory approval of a Licensed Product anywhere else in the world
			
	(ix)	 	 [***]
	  	Achieving at least fifty million (US$50,000,000) in Net Sales of a Licensed Product within a consecutive twelve (12) month period

  
 6 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 (d)    an earned royalty of one percent (1%) on Net Sales of Licensed
Products by LICENSEE, Sublicensees and/or its Affiliate(s); provided, however, that the earned royalty due on Net Sales of Combination Product by LICENSEE, Sublicensees and/or its Affiliate(s) shall be calculated as below: 

Earned Royalties due UNIVERSITY = [A/(A+B)] x Royalty Rate on Net Sales of the Licensed Products x Net Sales of Combination Product, where:

 A is the separately listed Net Sale unit price of the Licensed Product or Licensed Product components; and 

B is the separately listed sale prices of the individual products or product components, respectively, that satisfy the requirements outlined
in Paragraph 1.3 (“Combination Products”). 
 In the event LICENSEE is required to pay royalties to one or more third parties for rights necessary
to make, use or sell Licensed Products, LICENSEE may deduct [***] from the earned royalties payable to UNIVERSITY for every [***] LICENSEE actually pays to said third parties; provided, however, in no event shall the amount payable to UNIVERSITY be
less than [***] of the amount otherwise due (Abatement”). 
 (e)    A percentage of all Sublicense fees received by
LICENSEE from its Sublicensees, according to the following schedule: 
  

			
	 Percentage
	  	Timing of Sublicense
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 (f)    Beginning the calendar year of commercial sales of the first Licensed Product by
LICENSEE, its Sublicensee, or an Affiliate and if the total earned royalties paid by LICENSEE under Paragraphs 3.1(d) and (f) to UNIVERSITY cumulatively amounts to less than: 

(i)    [***]; 

(ii)    [***]; 

(iii)    [***], 

LICENSEE shall pay to UNIVERSITY the above amounts as a minimum annual royalty on or before February 28 following the last quarter of such
year the difference between amount noted above and the total earned royalty paid by LICENSEE for such year under Paragraphs 3.1(d) and (f); provided, however, that for the year of commercial sales of the first Licensed Product, the amount of minimum
annual royalty payable shall be pro-rated for the number of months remaining in that calendar year. 

(g)    All fees and royalty payments specified in Paragraphs 3.1(a) through 3.1(f) above shall be paid by LICENSEE pursuant
to Paragraph 4.3 and shall be delivered by LICENSEE to UNIVERSITY as noted in Paragraph 10.1. 
 (h)    The royalties
under Sections 3.1(d) and 3.1(e) continue, on a country-by-country basis, until the expiration of the last to expire patent containing a Valid Claim covering the
applicable Licensed Product or Licensed Method. 

  
 7 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 3.2    Due Diligence. 

(a)    LICENSEE shall use Commercially Reasonable Efforts, either directly or through its Affiliate(s) or Sublicensee(s)
to: 
 (i)    diligently proceed with the development, manufacture and sale of Licensed Products; 

(ii)    annually spend not less than Three hundred thousand dollars (US$300,000) for the development of Licensed Products
during the first five (5) years of this Agreement. LICENSEE may, at its sole option, fund the research of any one of the Inventors employed by UCSD and credit the amount of such funding actually paid to UCSD against its obligation under this
paragraph; 
 (iii)    submit an IND covering Licensed Products to the United States FDA by December 31, 2015; 

(iv)    initiate a Phase II clinical trial using a Licensed Product by December 31, 2018; 

(v)    initiate a Phase III clinical trial using a Licensed Product By December 31, 2021; 

(vi)    submit a NDA application to the United States FDA or an equivalent regulatory approval in another jurisdiction
covering Licensed Products by December 31, 2026; 
 (vii)    submit a regulatory approval application in another
jurisdiction covering Licensed Products by December 31, 2028 
 (viii)    market Licensed Products in the United
States within twelve (12) months after receiving regulatory approval to market such Licensed Products; 

(ix)    fill the market demand for Licensed Products following commencement of marketing at any time during the term of
this Agreement in those territories where LICENSEE has elected to make, use or sell Licensed Products. Notwithstanding the foregoing, both parties acknowledge that the Licensed Product is a biologic and therefore subject to a ramp up time
appropriate to production of a biologic in the event of unexpected or increasing market demand. Accordingly, it shall not be a breach of this agreement should LICENSEE fail to fill the market demand within the first year after approval and
thereafter in the event of such unexpected or increasing market demand; provided, however, that LICENSEE takes prompt reasonable steps to accommodate the change in demand. 

(x)    obtain all necessary governmental approvals for the manufacture, use and sale of Licensed Products. 

(b)    If LICENSEE should reasonably believe it may fail to meet any of its obligations specified in Paragraphs
3.3(a)(iii)-(iv) and provides UNIVERSITY with notice of its concern at least [***] months prior to the relevant date of such obligation, LICENSEE and UNIVERSITY shall enter into good faith negotiations to amend this Agreement to extend the dates for
satisfaction of such obligation and, if applicable, the remaining obligations. 

  
 8 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 (c)    If LICENSEE fails to perform its obligations specified in
Paragraphs 3.3(a)(i)-(ii) or the negotiations pursuant to Paragraph 3.3(b) fail to result in an amendment to this Agreement and LICENSEE fails to perform any of its obligations specified in Paragraphs 3.3(a)(iii)-(iv), then UNIVERSITY shall have the
right and option to terminate this Agreement. This right, if exercised by UNIVERSITY, supersedes the rights granted in Article 2. 

ARTICLE 4. REPORTS, RECORDS AND PAYMENTS 

4.1    Reports. 

(a)    Progress Reports. 

If requested, six months after the Effective Date, UNIVERSITY may request a progress report, and then on the subsequent anniversary after
Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, within [***] days after receipt of UNIVERSITY’s progress report form, LICENSEE will provide an annual progress report relating to
LICENSEE’s (and Affiliate’s and Sublicensee’s) activities for the preceding twelve months to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same (the “Progress Report”).
Such Progress Reports shall be due within [***] days after the anniversary of the Effective Date of this Agreement and include a summary of work completed, summary of work in progress, current schedule of anticipated events or milestones, market
plans for introduction of Licensed Products, and summary of resources (dollar value) spent in the reporting period. The Progress Reports referred to in this Section 4.1 (a) should be marked with the following title and case number:
“License Agreement between UCSD and Neotope, Inc. for case 2002-035.” Progress Reports shall be submitted as attachment to UCSD’s email address:
tto-reports@ucsd.edu. 
 (b)    Royalty Reports 

After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY semi-annual royalty reports on
or before each of May 31 and November 30 of each year. Each May and November royalty report shall cover LICENSEE’S (and each Affiliate’s and Sublicensee’s) activities October through March and April through August,
respectively, and shall show: 
 (i)    the date of first commercial sale of a Licensed Product in each country; 

(ii)    the gross sales, deductions as provided in Paragraph 1.6 (Net Sales), and Net Sales during the most recently
completed calendar quarter and the royalties, in US dollars, payable with respect thereto; 
 (iii)    the number of each
type of Licensed Product sold; 
 (iv)    Sublicense fees and royalties received during the most recently completed
calendar quarter in US dollars, payable with respect thereto; 

  
 9 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 (v)    the method used to calculate the royalties; and 

(vi)    the exchange rates used. 

If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE
shall so report. The reports referred to in this Section 4.1(b) should be marked with the following title and case number: “License Agreement between UCSD and PROTHENA BIOSCIENCES for case
2002-035” and shall be submitted as attachment to UCSD’s email address: tto-reports@ucsd.edu. 

4.2    Records & Audits. 

(a)    LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, accurate and correct records of all
Licensed Products manufactured, used, and sold, and Sublicense fees received under this Agreement. Such records shall be retained by LICENSEE for at least [***] years following a given reporting period. 

(b)    All records shall be available during normal business hours for inspection at the expense of UNIVERSITY by
UNIVERSITY’s Internal Audit Department or by a Certified Public Accountant selected by UNIVERSITY and in compliance with the other terms of this Agreement for the sole purpose of verifying reports and payments or other compliance issues. Such
inspector shall not disclose to UNIVERSITY any information other than information relating to the accuracy of reports and payments made under this Agreement or other compliance issues. In the event that any such inspection shows an under reporting
and underpayment in excess of [***] for any twelve-month (12-month) period, UNIVERSITY shall provide LICENSEE with a report of such inspector’s findings and conclusions. If LICENSEE does not dispute the
report, then LICENSEE shall pay the cost of the audit as well as any additional sum that would have been payable to UNIVERSITY had the LICENSEE reported correctly, plus an interest charge at a rate of [***] per year. Such interest shall be
calculated from the date the correct payment was due to UNIVERSITY up to the date when such payment is actually made by LICENSEE. For underpayment not in excess of [***] for any twelve-month (12-month) period,
LICENSEE shall pay the difference within [***] days without interest charge or inspection cost. Any unresolved dispute between the parties regarding the report shall first be referred to the Chief Financial Officer of LICENSEE and UNIVERSITY’s
Assistant Vice Chancellor, Technology Transfer. If the dispute has not been resolved within [***] days after such referral, then the parties may pursue any and all remedies that may be available under this Agreement, at law and in equity. 

4.3    Payments. 

(a)    All fees, reimbursements and royalties due UNIVERSITY shall be paid in United States dollars and all checks shall be
made payable to “The Regents of the University of California”, referencing UNIVERSITY’s taxpayer identification number, 95-6006144, and sent to UNIVERSITY according to Paragraph 10.1
(Correspondence). When Licensed Products are sold in currencies other than United States dollars, LICENSEE shall first determine the earned royalty in the currency of the country in which Licensed Products were sold and then convert the amount into
equivalent United States funds, using the exchange rate quoted in the Wall Street Journal on the last business day of the applicable reporting period. 

  
 10 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 (b)    Royalty Payments 

(i)    Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or
Affiliate. 
 (ii)    LICENSEE shall pay earned royalties quarterly [***]. Each such payment shall be for earned
royalties accrued within LICENSEE’s most recently completed calendar quarter. 
 (iii)    Royalties earned on sales
occurring in any country outside the United States (“Ex-US”) or royalty income arising from any Sublicense granted pursuant to this Agreement Ex-US shall not
be reduced by LICENSEE for any taxes, fees, or other charges imposed by the government of such country affecting the payment of royalty income to UNIVERSITY, except as allowed under Paragraph 1.7. Payments are actually made by LICENSEE or
SUBLICENSEE in fulfillment of UNIVERSITY’s tax liability in any particular country may be credited against earned royalties or fees due UNIVERSITY for that country. LICENSEE shall pay all bank charges resulting from the transfer of such royalty
payments. LICENSEE shall deliver to UNIVERSITY, upon UNIVERSITY’s request, proof of payment of all such taxes. Each party shall provide assistance to the other party in seeking any benefits available to such party with respect to government tax
withholdings by any relevant law or double tax treaty. 
 (iv)    If at any time legal restrictions prevent the prompt
remittance of part or all royalties by LICENSEE with respect to any country where a Licensed Product is sold or a Sublicense is granted pursuant to this Agreement, LICENSEE shall convert the amount owed to UNIVERSITY into US currency and shall pay
UNIVERSITY directly from its US sources of funds for as long as the legal restrictions apply. 
 (v)    In the event that
any patent or patent claim within Patent Rights is held invalid in a final decision by a patent office from which no appeal or additional patent prosecution has been or can be taken, or by a court of competent jurisdiction and last resort and from
which no appeal has or can be taken, all obligation to pay royalties based solely on that patent or claim or any claim patentably indistinct therefrom shall cease as of the date of such final decision. LICENSEE shall not, however, be relieved from
paying any royalties that accrued before the date of such final decision, that are based on another patent or claim not involved in such final decision. 

(vi)    Royalty payments under Article 3, recoveries and settlements under Article 5, and royalty reports under 4.1(b)
shall be rendered for any and all Licensed Products even if due after expiration of the Agreement. If no utilization of Technology and no applicable Patent Rights existed in the Territory at the time of any making, use, sale, offer for sale, or
import, then no royalty payments or royalty reports shall be due. 

  
 11 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 (c)    Late Payments. In the event royalty, reimbursement and/or fee
payments are not received by UNIVERSITY when due, LICENSEE shall pay to UNIVERSITY the interest charges at a rate of [***] per year. Such interest shall be calculated from the date payment was due until actually received by UNIVERSITY. 

ARTICLE 5. PATENT MATTERS 

5.1    Patent Prosecution and Maintenance. 

(a)    LICENSEE agrees to diligently prosecute and maintain the patents and patent applications described under the Patent
Rights. LICENSEE shall provide UNIVERSITY with copies of all relevant documentation relating to such prosecution and UNIVERSITY shall keep this documentation confidential. The counsel shall take instructions only from LICENSEE. Additional filings
related to the Invention shall determine inventorship in accordance with US patent law and ownership shall follow inventorship. All patent filings and all patent prosecution decisions and related filings (e.g. responses to office actions) shall be
at LICENSEE’s final discretion (prosecution includes, but is not limited to, interferences, oppositions and any other inter partes matters originating in a patent office). 

(b)    LICENSEE shall consider amending any patent application in Patent Rights to include claims reasonably requested by
UNIVERSITY to protect the products contemplated to be sold by LICENSEE under this Agreement. 
 (c)    If LICENSEE
decides to discontinue prosecution or maintenance of any Patent Right, LICENSEE agrees to notify UNIVERSITY in sufficient time for UNIVERSITY to decide whether they wish to assume responsibility for that patent or application. UNIVERSITY will notify
LICENSEE of their decision in a timely manner. If UNIVERSITY reasonably disagrees with the abandonment of said Patent Right LICENSEE shall continue prosecution or maintenance of such Patent Right as set forth in Sections 5.1(a) and (b). 

(d)    Should LICENSEE in its sole discretion decide to apply for an extension of the term of any patent in Patent Rights
if appropriate under the Drug Price Competition and Patent Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts of this law., LICENSEE shall prepare all documents for such application, and UNIVERSITY shall execute
such documents and take any other additional action as LICENSEE reasonably requests in connection therewith. 
 5.2    Patent
Infringement. 
 (a)    In the event that UNIVERSITY (to the extent of the actual knowledge of the licensing
professional responsible for the administration of this Agreement) or LICENSEE (to the extent of the actual knowledge of LICENSEE’s employee(s) responsible for the administration of this Agreement) learns of infringement of potential commercial
significance in the Field of any Valid Claim, the knowledgeable party will provide the other (i) with written notice of such infringement and (ii) with any evidence of such infringement available to it (the “Infringement
Notice”). During the period in which, and in the jurisdiction where, LICENSEE has exclusive rights under this Agreement, neither UNIVERSITY nor LICENSEE will notify a third party (including the infringer) of infringement or put such third party
on notice of the 

  
 12 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 
existence of any Patent Rights without first obtaining consent of the other. If LICENSEE notifies a third party of infringement or puts such third party on notice of the existence of any Patent
Rights with respect to such infringement without first obtaining the written consent of UNIVERSITY and UNIVERSITY is sued in declaratory judgment, UNIVERSITY shall have the right to terminate this Agreement immediately without the obligation to
provide [***] days’ notice as set forth in Paragraph 7.1. Both UNIVERSITY and LICENSEE will use their reasonably diligent efforts to cooperate with each other to abate such infringement without litigation. 

(b)    If infringing activity of potential commercial significance by the infringer has not been abated within [***] days
following the date the Infringement Notice takes effect, LICENSEE shall have the first right to institute suit for patent infringement against the infringer. UNIVERSITY may voluntarily join such suit, but may not thereafter commence suit against the
infringer for the acts of infringement that are the subject of LICENSEE’s suit or any judgment rendered in that suit. LICENSEE may not join UNIVERSITY in a suit initiated by LICENSEE without UNIVERSITY’s prior written consent. Since UCSD
does not have the authority to commit UNIVERSITY to joining such suit, UCSD shall request and recommend that UNIVERSITY, if deemed to be a necessary party by a court of competent jurisdiction and in the absence of a conflict that would prevent
UNIVERSITY from doing so, join such suit at LICENSEE’S expense. LICENSEE will pay any costs incurred by UNIVERSITY arising out of such suit, including but not limited to, any legal fees of counsel that UNIVERSITY selects and retains to
represent it in the suit. 
 (c)    If, within [***] days following the date the Infringement Notice takes effect,
infringing activity of potential commercial significance by the infringer has not been abated and if LICENSEE has not brought suit against the infringer, UNIVERSITY may institute suit for patent infringement against the infringer. If UNIVERSITY
institutes such suit, LICENSEE may not join such suit without UNIVERSITY’s consent and may not thereafter commence suit against the infringer for the acts of infringement that are the subject of UNIVERSITY’s suit or any judgment rendered
in that suit. UNIVERSITY shall not admit the invalidity or unenforceability of any Patent Rights without LICENSEE’s prior written consent. 

(d)    Notwithstanding anything to the contrary in this Agreement: 

(A)    in the event that the infringement or potential infringement pertains to an issued patent included within the Patent
Rights and written notice is given under any statute expediting litigation (e.g. the Drug Price Competition and Patent Term Restoration Act of 1984 and/or foreign counterparts of this Law) (“Act”), then the party in receipt of such notice
under the Act (in the case of UNIVERSITY to the extent of the actual knowledge of the licensing officer responsible for the administration of this Agreement) shall provide the Infringement Notice to the other party promptly. If the time period is
such that the LICENSEE will lose the right to pursue legal remedy for infringement by not notifying a third party or by not filing suit, the notification period and the time period to file suit will be accelerated to within [***] days of the date of
such notice under the Act to either party. 
 (B)    The parties shall cooperate to comply with the provisions of the
Patient Protection and Affordable Care Act (H.R. 3590) required to protect and enforce Patent Rights including without limitation the Public Health Service Act (42 U.S.C. 262) Sections 351 (1)(1 )-(6), (8) and (9). 

  
 13 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 (e)    Any recovery or settlement received in connection with any suit
will first be shared by UNIVERSITY and LICENSEE proportionately to cover the litigation costs each incurred except as to those of its costs paid by the other party to this Agreement. In any suit initiated by LICENSEE, any recovery in excess of
litigation costs will be shared between LICENSEE and UNIVERSITY as follows: (A) UNIVERSITY will receive [***] of the recovery if UNIVERSITY was not a party in the; or (B) UNIVERSITY will receive [***] of the recovery if UNIVERSITY was a
party in the litigation. In any suit initiated by UNIVERSITY, any recovery in excess of litigation costs will be shared between LICENSEE and UNIVERSITY as follows: (A) LICENSEE will receive fifteen percent (15%) of the recovery if LICENSEE was
not a party in the suit; or (B) LICENSEE will receive [***] of the recovery if LICENSEE was a party in the litigation. UNIVERSITY and LICENSEE agree [***]. LICENSEE and UNIVERSITY will [***]. 

(f)    Any agreement made by LICENSEE for purposes of settling litigation or other dispute shall comply with the
requirements of Section 2.2 (Sublicenses) of this Agreement. 
 (g)    Each party will cooperate with the other in
litigation proceedings instituted hereunder but at the expense of the party who initiated the suit (unless such suit is being jointly prosecuted by the parties). 

(h)    Any litigation proceedings will be controlled by the party bringing the suit, except that UNIVERSITY may be
represented by counsel of its choice in any suit brought by LICENSEE. 
 5.3    Patent Marking. LICENSEE shall mark all Licensed
Products made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws. LICENSEE shall be responsible for all monetary and legal liabilities arising from or caused by
(i) failure to abide by applicable patent marking laws and (ii) any type of incorrect or improper patent marking. 
 ARTICLE 6.
GOVERNMENTAL MATTERS 
 6.1    Governmental Approval or Registration. If this Agreement or any associated transaction is
required by the law of any nation to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so. LICENSEE shall notify UNIVERSITY if it becomes aware that this Agreement is subject to a United
States or foreign government reporting or approval requirement. LICENSEE shall make all necessary filings and pay all costs including fees, penalties, and all other
out-of-pocket costs associated with such reporting or approval process. 

6.2    Export Control Laws. LICENSEE shall observe all applicable United States and foreign laws with respect to the transfer of
Licensed Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations and the Export Administration Regulations. 

  
 14 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 ARTICLE 7. TERMINATION OR EXPIRATION OF THE AGREEMENT 

7.1    Termination by UNIVERSITY. 

(a)    If LICENSEE fails to perform or violates any term of this Agreement, then UNIVERSITY may give written notice of
default (“Notice of Default”) to LICENSEE. If LICENSEE fails to cure the default within sixty (60) days of the Notice of Default, UNIVERSITY may terminate this Agreement and the license granted herein by a second written notice
(“Notice of Termination”) to LICENSEE. If a Notice of Termination is sent to LICENSEE, this Agreement shall automatically terminate on the effective date of that notice. Termination shall not relieve LICENSEE of its obligation to pay any
fees owed at the time of termination and shall not impair any accrued right of UNIVERSITY. During the term of any such Notice of Default or period to cure, to the extent the default at issue is a failure to pay past or ongoing Patent Costs as
provided for under this Agreement, UNIVERSITY shall have no obligation to incur any new Patent Costs under this Agreement and shall have no obligation to further prosecute Patent Rights or file any new patents under Patent Rights. 

(b)    This Agreement will terminate immediately, without the obligation to provide sixty (60) days’ notice as
set forth in Paragraph 7.1(a), if LICENSEE files a claim including in any way the assertion that any portion of UNIVERSITY’s Patent Rights is invalid or unenforceable where the filing is by the LICENSEE, a third party on behalf of the LICENSEE,
or a third party at the written urging of the LICENSEE. 
 (c)    This Agreement shall automatically terminate without
the obligation to provide sixty (60) days’ notice as set forth in Paragraph 7.1(a) upon the filing of a petition for relief under the United States Bankruptcy Code by or against the LICENSEE as a debtor or alleged debtor. 

7.2    Termination by LICENSEE. 

(a)    LICENSEE shall have the right at any time and for any reason to terminate this Agreement upon a ninety (90) day
written notice to UNIVERSITY. Said notice shall state LICENSEE’s reason for terminating this Agreement. 

(b)    Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or liability accrued under this
Agreement prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes effective. Termination shall not affect in any manner any rights of UNIVERSITY arising under this Agreement prior to
termination. 
 7.3    Survival on Termination or Expiration. The following Paragraphs and Articles shall survive the termination
or expiration of this Agreement: 
 (a)    Article 4 (REPORTS, RECORDS AND PAYMENTS), to the extent by their nature the
applicable provisions of Article 4 would be reasonably expected to survive. 
 (b)    Article 8 (LIMITED WARRANTY AND
INDEMNIFICATION); 
 (c)    Article 9 (USE OF NAMES AND TRADEMARKS); and 

(d)    Article 10. 

  
 15 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 ARTICLE 8. LIMITED WARRANTY AND INDEMNIFICATION 

8.1    Limited Warranty. 

(a)    UNIVERSITY warrants that it has the lawful right to grant this license. This warranty does not include Patent Rights
to the extent assigned, or otherwise licensed, by UNIVERSITY’s inventors to third parties. 
 (b)    The license
granted herein are is provided “AS IS” and without WARRANTY OF MERCHANTABILITY or WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE or any other warranty, express or implied. UNIVERSITY makes no representation or warranty that the Licensed
Product, Licensed Method or the use of Patent Rights will not infringe any other patent or other proprietary rights. 

(c)    NEITHER PARTY WILL BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS,
ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT, OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY THE OTHER PARTY, SUBLICENSEES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL
CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. ALSO, UNIVERSITY WILL NOT BE LIABLE FOR ANY DIRECT DAMAGES SUFFERED BY
LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO PATENT RIGHTS TO THE EXTENT ASSIGNED, OR OTHERWISE LICENSED, BY UNIVERSITY’S INVENTORS TO THIRD PARTIES. 

(d)    Nothing in this Agreement shall be construed as: 

(i)    a warranty or representation by UNIVERSITY as to the validity or scope of any Patent Rights; 

(ii)    a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in
this Agreement is or shall be free from infringement of patents of third parties; 
 (iii)    an obligation to bring or
prosecute actions or suits against third parties for patent infringement except as provided in Section 5.2 hereof; 

(iv)    conferring by implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY other than
Patent Rights as defined in this Agreement, regardless of whether those patents are dominant or subordinate to Patent Rights; or 

(v)    an obligation to furnish any know-how not provided in Patent Rights. 

8.2    Indemnification. 

(a)    LICENSEE will, and will require Sublicensees to, indemnify, hold harmless, and defend UNIVERSITY and its officers,
employees, and agents; the sponsors of the 

  
 16 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 
research that led to the Invention; and the inventors of patents or patent applications under Patent Rights, and their employers; against any and all product liability claims, suits, losses,
damages, costs, fees, and expenses resulting from, or arising out of, the exercise of this license or any Sublicense. 

(b)    LICENSEE, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement
and obtain, keep in force and maintain insurance or an equivalent program of self-insurance as follows: 
 comprehensive or commercial
general liability insurance (contractual liability included) with limits of at least: 
 (i)    [***] 

(ii)    [***] 

(iii)     Worker’s Compensation as legally required in the jurisdiction in which the LICENSEE is doing business; and

 (iv)    the coverage and limits referred to above shall not in any way limit the liability of LICENSEE. 

(c)    UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought against UNIVERSITY in respect of which
UNIVERSITY intends to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of any claims under this Article. LICENSEE will not settle any claim against UNIVERSITY without UNIVERSITY’s
written consent, where (a) such settlement would include any admission of liability or admission of wrong doing on the part of the indemnified party, (b) such settlement would impose any restriction on UNIVERSITY/indemnified party’s
conduct of any of its activities, or (c) such settlement would not include an unconditional release of UNIVERSITY/indemnified party from all liability for claims that are the subject matter of the settled claim. 

ARTICLE 9. USE OF NAMES AND TRADEMARKS 

9.1    Except as provided in 9.3, nothing contained in this Agreement confers any right to use in advertising, publicity, or other
promotional activities any name, trade name, trademark, or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing). Unless required by law, and except for investor presentations and in
connection with due diligence, the use by LICENSEE of the name, “The Regents of the University of California” or the name of any campus of the University of California in advertising, publicity, or other promotional activities is
prohibited, without the express written consent of UNIVERSITY. 
 9.2    UNIVERSITY may disclose to the Inventors the terms and
conditions of this Agreement upon their request. If such disclosure is made, UNIVERSITY shall request the Inventors not disclose such terms and conditions to others. 

9.3    The parties may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to third parties, but shall
not, without the prior written consent of the other party, such consent not to be unreasonably withheld, conditioned, or delayed, disclose the financial terms of this Agreement to third parties, except where required by law to do so, such as under
the California Public Records Act. 

  
 17 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 LICENSEE does not grant UNIVERSITY (including UCSD) permission to include LICENSEE’s name and a link to
LICENSEE’s website in UNIVERSITY’s and UCSD’s annual reports and on UNIVERSITY’s (including UCSD’s) websites that showcase technology transfer related stories. 

ARTICLE 10. MISCELLANEOUS PROVISIONS 

10.1    Correspondence. Any notice or payment required to be given to either party under this Agreement shall be deemed to have
been properly given and effective: 
 (a)    on the date of delivery if delivered in person, or 

(b)    five (5) days after mailing if mailed by first-class or certified mail, postage paid, to the respective
addresses given below, or to such other address as is designated by written notice given to the other party. 
 If sent to LICENSEE: 

Notices:         Neotope Biosciences Limited 

                  
    25-28 North Wall Quay 

                      Dublin 1
Ireland 

                      Attention:
Director 
 With a copy to: 

Prothena Biosciences Inc, 
 650
Gateway Boulevard 
 South San Francisco, CA 94080 

Attn: Tara Nickerson 

Invoices:            accounting@prothena.com 

If sent to UNIVERSITY by mail: 

University of California, San Diego 

Technology Transfer Office 
 9500
Gilman Drive, Mail Code 0910 
 La Jolla, CA 92093-0910 Attention: 

Assistant Vice Chancellor 
 If
sent to UNIVERSITY by courier: 
 University of California, San Diego 

Technology Transfer Office 
 10300
North Torrey Pines Road 
 Torrey Pines Center North, Third Floor 

La Jolla, CA 92037 
 Attention:
Assistant Vice Chancellor 

  
 18 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 10.2    Secrecy. 

(a)    “Confidential Information” shall mean information, relating to the Invention and the Patent Rights, and
information disclosed by a party to the other party in connection with negotiation, terms and performance of this Agreement which if disclosed in writing shall be marked “Confidential”, or if first disclosed otherwise, shall within [***]
days of such disclosure be reduced to writing by UNIVERSITY and sent to LICENSEE: 
 (b)    The receiving party shall:

 (i)    use the Confidential Information for the sole purpose of performing under the terms of this Agreement; 

(ii)    safeguard Confidential Information against disclosure to others with the same degree of care as it exercises with
its own data of a similar nature; 
 (iii)    except as otherwise permitted herein, not disclose Confidential Information
to others (except to its employees (not applicable to UNIVERSITY’s employees, except to the extent related to the terms of this Agreement), agents, Sublicensees, Affiliates or consultants who are bound to the receiving party by a like
obligation of confidentiality) without the express written permission of the disclosing party, except that the receiving party shall not be prevented from using or disclosing any of the Confidential Information that: 

(A)    the receiving party can demonstrate by written records was previously known to it; 

(B)    is now, or becomes in the future, public knowledge other than through acts or omissions of the receiving party;

 (C)    is lawfully obtained by the receiving party from sources independent of disclosing party; or 

(D)    is required to be disclosed by law or a court of competent jurisdiction; and 

(c)    The secrecy obligations of the parties with respect to Confidential Information shall continue for a period ending
[***] years from the termination date of this Agreement. 
 (d)    Notwithstanding the foregoing, LICENSEE may, without
UNIVERSITY’s prior consent, disclose this Agreement to potential Sublicensees in connection with due diligence. 

10.3    Assignability. This Agreement shall be binding upon and inure to the benefit of LICENSEE and UNIVERSITY and their
respective successors and permitted assigns. Neither party may delegate its obligations under this Agreement or assign or otherwise transfer this Agreement without the prior written consent of the other party; provided, however, that either party
may, without prior consent, assign this Agreement and/or the rights and obligations thereunder to an Affiliate, or to a third party who acquires all, or substantially all of the business relating to the subject matter of this Agreement. The parties
agree to notify the other party of any such assignment. 

  
 19 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 10.4    No Waiver. No waiver by either party of any breach or default of any
covenant or agreement set forth in this Agreement shall be deemed a waiver as to any subsequent and/or similar breach or default. 

10.5    Governing Laws. THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA,
but the scope and validity of any patent or patent application shall be governed by the applicable laws of the country of the patent or patent application. 

10.6    Force Majeure. A party to this Agreement may be excused from any performance required herein if such performance is
rendered impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or
other serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the non-performing party’s obligations herein shall resume. 

10.7    Headings. The headings of the several sections are inserted for convenience of reference only and are not intended to be a
part of or to affect the meaning or interpretation of this Agreement. 
 10.8    Entire Agreement. This Agreement embodies the
entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof; provided, however, that the Secrecy Agreement shall
remain in full force and effect for all disclosures between the parties prior to the Effective Date of this Agreement. 

10.9    Amendments. No amendment or modification of this Agreement shall be valid or binding on the parties unless made in writing
and signed on behalf of each party. 
 10.10    Severability. In the event that any of the provisions contained in this Agreement
is held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if the invalid, illegal, or
unenforceable provisions had never been contained in it. 
 IN WITNESS WHEREOF, both UNIVERSITY and LICENSEE have executed this Agreement, in
duplicate originals, by their respective and duly authorized officers on the day and year written. 
  

									
	NEOTOPE BIOSCIENCES LTD.	 		 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:
					
	By:	 	 /s/ Shane
Cooke                                        
                
	 		 	By:	 	 /s/ Jane
Moores                                        

		 	(Signature)	 		 		 	(Signature)
	Name:	 	Shane Cooke	 		 		 	Jane Moores, PH.D.
	Title:	 	Director	 		 		 	Assistant Vice Chancellor-Technology Transfer
					
	Date:	 	04 November 2013	 		 	Date:	 	10/21/13

  
 20 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 I concur in Sections 2.3(e) and 10.2 (subject to UNIVERSITY’s rights in Sections 2.3a-c) only as they exist on the date of my signature. I am not a party to this Agreement. 
  

			
	By:	 	 /s/ Eliezer Masliah

		 	(Signature)
	Dr. Eliezer Masliah

  
 21 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 Exhibit A 

Created 10/23/2012 
 [***] 

  
 1 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.EX-10.1B

 Exhibit 10.1(b) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 LICENSE AGREEMENT 

AMENDMENT NUMBER ONE 
 This License Agreement
Amendment Number One (the “Amendment”) is made as of January 15, 2014 (the “Amendment Effective Date”) by and between Neotope Biosciences Limited, a private limited company incorporated under the laws of Ireland with offices
at 25-28 North Wall Quay, Dublin 1, Ireland (“LICENSEE”) and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street,
Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Technology Transfer Office, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910
(“UCSD”). 
 RECITALS 
 WHEREAS,
LICENSEE and UNIVERSITY have previously entered a license agreement effective November 4, 2013 (the “Agreement”); 
 WHEREAS, LICENSEE wishes
to sublicense its rights under the Agreement to F. HOFFMANN-LA ROCHE LTD, a Swiss corporation with a principal place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and HOFFMANN-LA ROCHE INC., a New Jersey corporation with a principal place of business at 340 Kingsland Street, Nutley, New Jersey, U.S.A. 07110 (“Roche Nutley”, and together with Roche Basel,
“Roche”); 
 WHEREAS, LICENSEE and Roche have entered into a separate research, development and commercialization agreement relating to Licensed
Products and Patent Rights and other products and patent rights (the “Collaboration Agreement”); 
 WHEREAS, Roche wishes to enter into a
Sublicense on terms that differ in some respects from the terms of the Agreement [***] and consistent with terms in the Collaboration Agreement; and 

WHEREAS, LICENSEE and UNIVERSITY mutually desire to amend the Agreement to modify certain terms acceptable to Roche; such modifications are applicable only to
the Roche Sublicense unless otherwise agreed between the parties; 
 NOW, THEREFORE, the parties agree as follows, effective as of the Amendment Effective
Date: 
 TERMS AND CONDITIONS 

1.    Section 1.2 of the Agreement shall be amended to read as follows: 

“1.2 “Combination Product” means a single pharmaceutical formulation containing as its active ingredients both a Licensed
Compound and one or more other therapeutically or prophylactically active ingredients or a combination therapy comprised of a Licensed Compound and one or more 

 
other therapeutically or prophylactically active products, priced and sold in a single package containing such multiple products or packaged separately but sold together for a single price in
each case, including all dosage forms, formulations, presentations, line extensions, and package configurations. All references to a Licensed Product in this Agreement shall be deemed to include a Combination Product. 

2.    Section 1.3 of the Agreement shall be amended to add the following sentence: 

“Notwithstanding the foregoing, the definition of Commercially Reasonable Efforts during the term of the Collaboration Agreement shall be
as set forth in Schedule 1.3.” 
 3.    Section 1.7 of the Agreement shall be amended to add the following paragraph: 

“Notwithstanding the foregoing, with respect to Licensed Products sold by Roche, its affiliates or sublicensees during the term of the
Collaboration Agreement, the foregoing provisions of this Section 1.7 shall not apply and instead the terms set forth in Schedule 1.7 shall apply.” 

4.    Article 1 of the Agreement shall be amended to add the following sections: 

“1.15    “Collaboration Agreement” means the License, Development, and Commercialization Agreement between
LICENSEE and Prothena Biosciences Inc, on the one hand, and Roche, on the other hand, dated December 11, 2013.” 
 1.16
    “Roche” means F .Hoffman-La Roche Ltd and Hoffmann-La Roche Inc.” 

5.    Section 2.2(b)(iii) of the Agreement shall be amended to add the following sentence: 

“For the avoidance of doubt, LICENSEE shall have no obligation to provide UNIVERSITY with a copy of any sublicense entered into between
Roche and its Affiliates or subcontractors. The obligation to provide UNIVERSITY with a copy of any sublicense with a non-affiliated third party for the commercial development of Licensed Products shall
remain.” 
 6.    Section 2.2(b)(iv) of the Agreement shall be amended to add the following sentence: 

“For the avoidance of doubt, LICENSEE shall have no obligation to collect payments from any sublicensee of Roche. The obligation to
guarantee such payments shall remain a provision of the Agreement.” 
 7.    Section 3.2(b) of the Agreement shall be amended
to read as follows: 
 “If LICENSEE should reasonably believe it may fail to meet any of its obligations specified in Paragraph
3.2(a)(iii)-(iv) or 3.2(d), as applicable, and provides UNIVERSITY with notice of its concern at least [***] months prior to the relevant date of such obligation, LICENSEE and UNIVERSITY shall enter into good faith negotiations to amend this
Agreement to extend the dates or otherwise modify the conditions for satisfaction of such obligations.” 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 8.    Section 3.2(c) of the Agreement shall be amended to read as follows: 

“If LICENSEE fails to perform its obligations specified in Paragraph 3.2(a)(i)-(ii) or 3.2(d), as applicable, or the negotiations pursuant
to Paragraph 3.2(b) fail to result in an amendment to this Agreement and LICENSEE fails to perform any of its obligations specified in Paragraphs 3.2(a)(iii)-(iv) or 3.2(d), as applicable, then UNIVERSITY shall have the right and option to terminate
this Agreement. This right, if exercised by UNIVERSITY, supersedes the rights granted in Article 2.” 
 9.    Section 3.2 of the
Agreement shall be amended to add new Section 3.2(d) as follows: 
 “(d) Notwithstanding the foregoing, during the term of the
Collaboration Agreement, Roche’s and LICENSEE’s and its Affiliates’ obligations of due diligence shall be subject to Schedule 3.2(d).” 

10.    Article 4 of the Agreement shall be amended to add the following introductory paragraph: 

“Except with respect to activities performed pursuant to the Collaboration Agreement during the term of the Collaboration Agreement,
Sections 4.1, 4.2 and 4.3 shall apply. In the case of activities performed pursuant to the Collaboration Agreement, the provisions set forth in Schedule 4 shall apply.” 

11.    Schedules 1.3, 1.7, 3.2(d) and 4 appended hereto as Exhibits A, B, C and D respectively, shall be added to the Agreement. 

12.    Except as modified herein, the Agreement remains in full force and effect and is hereby incorporated by this reference. Capitalized
terms not otherwise defined herein shall have the meanings contained in the Agreement. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

									
	Accepted and Agreed:	 		 		 	
			
	NEOTOPE BIOSCIENCES LIMITED	 		 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By:	 	 /s/ Shane Cook
	 		 	By:	 	 /s/ Jane C. Moores

	Name:	 	Shane Cooke	 		 	Name:	 	Jane C. Moores, Ph.D
	Title:	 	Director	 		 	Title:	 	Assistant Vice Chancellor, Technology Transfer
					
	Date:	 	17 January 2014	 		 	Date:	 	1/14/14

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT A 

Schedule 1.3 

Commercially Reasonable Efforts by Roche 

“Commercially Reasonable Efforts” means such level of efforts required to carry out such obligation in a sustained manner consistent with the
efforts that Roche devotes at the same stage of development or commercialization, as applicable, for its own internally developed pharmaceutical products in a similar area with similar market potential, at a similar stage of their product life
taking into account the existence of other competitive products in the market place or under development, the proprietary position of the product, the regulatory structure involved, the anticipated profitability of the product and other relevant
factors. It is understood that such product potential may change from time to time based upon changing scientific, business and marketing and return on investment considerations. The parties acknowledge that Roche (and its Affiliates) does not
always seek to market its own products in every country or seek to obtain regulatory approval in every country or for every potential indication. [***] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT B 

Schedule 1.7 
 Net Sales
Definition Applicable to Roche 
 “Net Sales” means, for a Licensed Product in a particular period, the amount calculated by subtracting from
the Sales of such Licensed Product for such period: (a) a lump sum deduction of [***] in lieu of those deductions that are not accounted for on a Licensed Product-by-Licensed Product basis, including
without limitation freight, postage charges, transportation insurance, packing materials for dispatch of goods, custom duties; (b) uncollectible amounts accrued during such period based on [***] in accordance with the then-currently used IFRS
in the calculation of Sales of such Licensed Product for such period; and (c) government mandated fees and taxes (excluding income or franchise taxes) and [***] in accordance with the then-currently used IFRS in the calculation of Sales of such
Licensed Product for such period, including, for example, any fees, taxes or other charges that become due in connection with [***]. For clarity, any given deduction shall be taken only under one of subsections (a) and (b), and only once in
calculating Net Sales. 
 [***] 
 “Sales” means, for
a Licensed Product in a particular period, the sum of (a) and (b) below: 
 (a)    The amount [***] with respect to
such Licensed Product for such period [***]. This amount reflects the [***] taken in accordance with the then-currently used IFRS. By way of example, the gross-to-net
deductions taken in accordance with IFRS as of the Effective Date include the following: 
 [***] 

For clarity, any given deduction shall be taken only under one of subsections (i) through (v), and only once in calculating Sales. For
purposes of clarity, sales by Roche and its Affiliates to any sublicensees that are not Affiliates of Roche shall be excluded from “Sales”, unless such sublicensees are end users of such Licensed Product. 

(b)    For sublicensees that are not Affiliates of Roche and not end users of such Licensed Product [***], the sales
amounts in the Territory reported to Roche and its Affiliates in accordance with [***]. For purposes of clarity, [***]. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT C 

Schedule 3.2(d) 
 Due
Diligence Obligations During Term of Collaboration Agreement 
 The milestones described in Paragraph 3.2(a)(iii) through Paragraph 3.2(a)(vii) have
been agreed upon for development of the Licensed Product designated as PRX002 (the “Lead Candidate”). Notwithstanding the foregoing, if LICENSEE fails to meet one of these provisions despite having diligently pursued the provision at
issue, as demonstrated in progress reports or other communication provided to UNIVERSITY or by receipt of notice from the FDA (or equivalent foreign regulatory agency, if applicable) of a delay or denial of approval for the Lead Candidate, and
LICENSEE or its Sublicensee must abandon the Lead Candidate, UNIVERSITY agrees to discuss in good faith with LICENSEE revising the diligence obligations of LICENSEE with respect to a new lead candidate. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT D 

Schedule 4 
 Reports,
Records and Payments under Roche Sublicense 
 4.1    Royalty Accounting and Reporting. 

(a)    Timing of Payments. Roche shall calculate royalties on Net Sales quarterly as of March 31, June 30,
September 30 and December 31 (each being the last day of an “Accounting Period”) and shall pay royalties on Net Sales to LICENSEE within [***] after the end of each Accounting Period in which such Net Sales occur. LICENSEE shall
pay UNIVERSITY an amount equal to such royalties received within [***] after receipt of such royalties from Roche. 

(b)    Currency Conversion. When calculating the Sales by Roche of any Licensed Product that occur in currencies other than
the Payment Currency, Roche and LICENSEE shall convert the amount of such Sales into Swiss Francs and then into the Payment Currency using Roche’s then-current internal foreign currency translation method actually used on a consistent basis in
preparing its audited financial statements (at the Effective Date, YTD average rate as reported by Reuters). 

(c)    Royalty Reporting. Within [***] after the end of each Accounting Period, Roche shall provide to LICENSEE for such
Accounting Period, on a Licensed Product-by-Licensed Product and country-by-country
basis, a written report with the following information, [***]: 
 (i)    the gross amount invoiced in
Swiss Francs; 
 (ii)    Sales in Swiss Francs, and the specific deductions applied in the calculation
of Sales pursuant to Schedule 1.7; 
 (iii)    Net Sales in Swiss Francs, and the specific
deductions applied in the calculation of Net Sales pursuant to Schedule 1.7; 

(iv)    exchange rate used for the conversion of Net Sales from Swiss Francs to the Payment Currency; 

(v)    Net Sales in the Payment Currency; 

(vi)    total royalty payable in the Payment Currency. 

[***] 
 4.2    Late Payment.
Any payment under this Agreement that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable Law, at [***] percentage points above the average
one-month Euro Interbank Offered Rate, as reported by Reuters from time to time, calculated on the number of days such payment is overdue. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 4.3    Currency and Method of Payment. Royalties on Net Sales and all other amounts
payable by Roche under this Agreement shall be paid by Roche in Dollars (the “Payment Currency”) to account(s) designated by LICENSEE. 

4.4    Records & Audits. 

(a)    Roche shall keep, and shall require its Affiliates and sublicensees to keep, accurate and correct records of all
Licensed Products manufactured, used, and sold, and sublicense fees received under this Agreement in sufficient detail to permit the other Party to confirm the accuracy of calculations of all payments made under this Agreement. Such records shall be
retained by Roche for at least [***] following a given reporting period. 
 (b)    At the expense of LICENSEE, LICENSEE
has the right to engage an internationally recognized independent public accountant (which shall not be deemed to be limited to the “Big Four” accounting firms) reasonably acceptable to Roche to perform, on behalf of LICENSEE, an audit of
such books and records of Roche and its Affiliates, that are deemed necessary by the independent public accountant for the period or periods requested by the auditing Party and the correctness of any financial report or payments made under this
Agreement. Upon timely request and at least [***] prior written notice from LICENSEE to Roche, such audit shall be conducted during regular business hours in such a manner as to not unnecessarily interfere with Roche’s normal business
activities, and shall be limited to results in the [***] prior to audit notification. Such audit shall not be performed more frequently than [***]. All information, data, documents and abstracts herein referred to shall be used only for the purpose
of verifying reports and payments made, and shall be treated as Roche’s confidential information. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]